Sandbox john: Difference between revisions

Jump to navigation Jump to search
 
(13 intermediate revisions by the same user not shown)
Line 1: Line 1:
==Testing area==
==Multiple Tables==
==Multiple Tables==
*0.
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
|+
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Disease}}
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Findings}}
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''[[DISEASE NAME]]'''
| style="padding: 5px 5px; background: #F5F5F5;" | PRESENTS WITH_____
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''DISEASE NAME'''
| style="padding: 5px 5px; background: #F5F5F5;" |PRESENTS WITH____
|-
|}


*1.  
*1.  
Line 176: Line 193:
|}
|}


==Play Time==
*4.
 
{|
{|
| valign=top |
| valign=top |
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #A1BCDD; text-align: center;">
{| style="cellpadding=0; cellspacing= 0; width: 290px;"
<font color="#FFF">
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Group A (May be sent home)}}
'''Pathogen-Based Therapy'''
|-
</font>
|<div class="mw-customtoggle-tableA1" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;▸&nbsp;&nbsp;Group criteria}}</div>
</div>
|-
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Neisseria meningitidis'''''
</font>
</div>
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Streptococcus pneumoniae'''''
</font>
</div>
<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Gram negative bacilli'''''
</font>
</div>
<div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Pseudomonas aeruginosa'''''
</font>
</div>
<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Staphylococci'''''
</font>
</div>
<div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Listeria monocytogenes'''''
</font>
</div>
<div class="mw-customtoggle-table07" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Haemophilus influenzae'''''
</font>
</div>
<div class="mw-customtoggle-table08" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Streptococcus agalactiae'''''
</font>
</div>
<div class="mw-customtoggle-table09" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Bacteroides fragilis'''''
</font>
</div>
<div class="mw-customtoggle-table10" style="cursor: pointer; border-radius: 0 0 5px 5px; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 400px; background: #4479BA;">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''''Fusobacterium spp.'''''
</font>
</div>
 
| valign=top |
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;"
{| class="mw-collapsible mw-expanded" id="mw-customcollapsible-tableA1"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients who do not have warning signs
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Able to tolerate adequate volumes of oral fluids <BR> OR <BR> ❑ Able to pass urine at least once every 6 hours
|}
|-
|<div class="mw-customtoggle-tableA2" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;▸&nbsp;&nbsp;Laboratory tests}}</div>
|-
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableA2"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Infants < 1 month}}
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Complete blood count <BR> ❑ Hematocrit (Hct)
|}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|<div class="mw-customtoggle-tableA3" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;▸&nbsp;&nbsp;Management}}</div>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV, q4h'''''
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableA3"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Adequate bed rest <BR> ❑ Adequate fluid intake <BR> ❑ Acetaminophen (Paracetamol)
|}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|<div class="mw-customtoggle-tableA4" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;&nbsp;&nbsp;Monitoring}}</div>
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 200 mg/kg/day IV, q6h'''''
|-
|-
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableA4"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients with stable Hct may be sent home. <BR> ❑ Daily review for disease progression: <BR> &nbsp;&nbsp; ❑ Decreasing white blood cell count <BR> &nbsp;&nbsp; ❑ Defervescence <BR> &nbsp;&nbsp; ❑ Warning signs (until out of critical period) <BR> ❑ Immediate return to hospital if development of any warning signs <BR> ❑ Written advice for management
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="cellpadding=0; cellspacing= 0; width: 290px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Infants 1-3 months}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Group B (Referred for in-hospital care)}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|<div class="mw-customtoggle-tableB1" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;▸&nbsp;&nbsp;Group criteria}}</div>
|-
| valign=top |
{| class="mw-collapsible mw-expanded" id="mw-customcollapsible-tableB1"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients with <u>any</u> of the warning signs: <BR> &nbsp;&nbsp; ❑ Abdominal pain or tenderness <BR> &nbsp;&nbsp; ❑ Persistent vomiting <BR> &nbsp;&nbsp; ❑ Clinical fluid accumulation <BR> &nbsp;&nbsp; ❑ Mucosal bleed <BR> &nbsp;&nbsp; ❑ Lethargy, restlessness <BR> &nbsp;&nbsp; ❑ Liver enlargment >2 cm <BR> &nbsp;&nbsp; ❑ Increase in hematocrit with rapid decrease in platelet count
|}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV, q4h'''''
|<div class="mw-customtoggle-tableB2" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;&nbsp;&nbsp;Laboratory tests}}</div>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableB2"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Complete blood count <BR> ❑ Hematocrit (Hct)
|}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 200 mg/kg/day IV, q6h''''' <BR> OR <BR> ▸ '''''[[Ceftriaxone]] 100 mg/kg/day IV, q12h'''''
|<div class="mw-customtoggle-tableB3" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;&nbsp;&nbsp;Management}}</div>
|-
|-
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table03" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableB3"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|> 3 months Immunocompetent Children; Adults < 55 years<sup>†</sup>}}
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Obtain reference Hct before fluid therapy <BR> ❑ Give isotonic solutions such as 0.9 % saline or Ringer’s Lactate <BR> &nbsp;&nbsp; ❑ Start with 5–7 ml/kg/h for 1–2 h <BR> &nbsp;&nbsp; ❑ Then reduce to 3–5 ml/kg/h for 2–4 h <BR> &nbsp;&nbsp; ❑  Then reduce to 2–3 ml/kg/h or less according to clinical response
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Reassess clinical status and repeat Hct
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If Hct remains the same or rises only minimally: <BR> &nbsp;&nbsp; ❑ Continue with 2–3 ml/kg/h for another 2–4 h <BR> ❑ If worsening of vital signs and rapidly rising Hct: <BR> &nbsp;&nbsp; ❑ Increase rate to 5–10 ml/kg/h for 1–2 h
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] Child: 60 mg/kg/day IV, q6h; Adult: 2 g/day IV, q12h'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Adjust fluid infusion rates
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Reduce intravenous fluids gradually when: <BR> &nbsp;&nbsp; ❑ Adequate urine output and/or fluid intake <BR> &nbsp;&nbsp; ❑ Hct deceases below the baseline value in a stable patient
|}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] Child: 200 mg/kg/day IV, q6h; Adult: 12 g/day IV, q4h''''' <BR> OR <BR> ▸ '''''[[Ceftriaxone]] Child: 100 mg/kg/day IV, q12h; Adult: 4 g/day IV, q12h''''' <BR> OR <BR> ▸ '''''[[Cefepime]] Child: 150 mg/kg/day IV, q8h; Adult: 6 g/day IV, q8h'''''
|<div class="mw-customtoggle-tableB4" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;&nbsp;&nbsp;Monitoring}}</div>
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL><sup></sup> Might be added [[Metronidazole]] Child: 30 mg/kg/day, q6h; Adult: 1500-2000 mg/day, q6h</SMALL>
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableB4"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Vital signs and peripheral perfusion (q1–4 until out of critical phase): <BR> &nbsp;&nbsp; ❑ Urine output (4–6 hourly) <BR> &nbsp;&nbsp; ❑ Hct (before and after fluid replacement, then 6–12 hourly) <BR> &nbsp;&nbsp; ❑ Blood glucose <BR> &nbsp;&nbsp; ❑ Renal function <BR> &nbsp;&nbsp; ❑ Liver function <BR> &nbsp;&nbsp; ❑ Coagulation profile
|}
|}
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table04" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="cellpadding=0; cellspacing= 0; width: 290px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Adults > 55 years; Alcoholics; Debilitating Illness}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Group C (Require emergency treatment)}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|<div class="mw-customtoggle-tableC1" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;▸&nbsp;&nbsp;Group criteria}}</div>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin]] Child: 200 mg/kg/day IV, q4h; Adult: 12 g/day IV, q4h'''''
| valign=top |
{| class="mw-collapsible mw-expanded" id="mw-customcollapsible-tableC1"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Patients with <u>any</u> of the warning signs: <BR> &nbsp;&nbsp; ❑ Abdominal pain or tenderness <BR> &nbsp;&nbsp; ❑ Persistent vomiting <BR> &nbsp;&nbsp; ❑ Clinical fluid accumulation <BR> &nbsp;&nbsp; ❑ Mucosal bleed <BR> &nbsp;&nbsp; ❑ Lethargy, restlessness <BR> &nbsp;&nbsp; ❑ Liver enlargment >2 cm <BR> &nbsp;&nbsp; ❑ Increase in hematocrit with rapid decrease in platelet count
|}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|<div class="mw-customtoggle-tableC2" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;▸&nbsp;&nbsp;Laboratory tests}}</div>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] Child: 60 mg/kg/day IV, q6h; Adult: 2 g/day IV, q12h'''''
| valign=top |
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableC2"
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC; width: 290px;" align=left | ❑ Complete blood count <BR> ❑ Hematocrit (Hct) <BR> ❑ Other organ function tests as indicated
|}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|<div class="mw-customtoggle-tableC3" style="cursor: pointer; padding: 0 0; font-weight: bold; background-color:#545454; border: 0.5px solid #999; font-size: 90%; border-radius: 0 0 0 0; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 20px; line-height: 20px; width: 290px; text-align: center;">{{fontcolor|#FFFFFF|&nbsp;&nbsp;▸&nbsp;&nbsp;Management}}</div>
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] Child: 200 mg/kg/day IV, q6h; Adult: 12 g/day IV, q4h''''' <BR> OR <BR> ▸ '''''[[Ceftriaxone]] Child: 100 mg/kg/day IV, q12h; Adult: 4 g/day IV, q12h''''' <BR> OR <BR> ▸ '''''[[Cefepime]] Child: 150 mg/kg/day IV, q8h; Adult: 6 g/day IV, q8h'''''
|}
|}
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table05" style="background: #FFFFFF;"
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-tableC3"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Specific Situations<sup></sup>}}
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Management of compensated shock
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Resuscitation with isotonic crystalloid at 5–10 ml/kg/h over 1 hour
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient improves: <BR> &nbsp;&nbsp; ❑ Reduce IV fluids gradually to 5–7 ml/kg/h for 1–2 h <BR> &nbsp;&nbsp; ❑ Then to 3–5 ml/kg/h for 2–4 h <BR> &nbsp;&nbsp; ❑ Then to 2–3 ml/kg/h for 2–4 h <BR> &nbsp;&nbsp; ❑ Then reduced further depending on hemodynamic status <BR> &nbsp;&nbsp; ❑ IV fluids can be maintained for up to 24–48 h
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient is still unstable: <BR> &nbsp;&nbsp; ❑ Check Hct after first bolus <BR> &nbsp;&nbsp; ❑ If Hct increases: repeat a second bolus at 10–20 ml/kg/h for 1 h <BR> &nbsp;&nbsp; ❑ If Hct decreases: transfuse as soon as possible
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ampicillin]] Child: 200 mg/kg/day IV, q4h; Adult: 12 g/day IV, q4h'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Management of hypotensive shock
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Resuscitation with crystalloid/colloid at 20 ml/kg for 15 min
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] Child: 60 mg/kg/day IV, q6h; Adult: 2 g/day IV, q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient improves: <BR> &nbsp;&nbsp; ❑ Control rate at 10 ml/kg/h for 1 h, then reduce gradually
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient is still unstable: <BR> &nbsp;&nbsp; ❑ Review the HCT taken before the first bolus <BR> &nbsp;&nbsp; ❑ If HCT was low: transfuse as soon as possible <BR> &nbsp;&nbsp; ❑ If HCT was high: IV colloids at 10–20 ml/kg for 0.5–1 h <BR> &nbsp;&nbsp; ❑ If patient is improving: reduce the rate to 7–10 ml/kg/h for 1–2 h
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftazidime]] Child: 150 mg/kg/day IV, q8h; Adult: 6 g/day IV, q8h''''' <BR> OR <BR> ▸ '''''[[Meropenem]] Child: 120 mg/kg/day IV, q8h; Adult: 3 g/day IV, q8h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ If patient is still unstable after second bolus: <BR> &nbsp;&nbsp; ❑ If HCT decreases: transfuse as soon as possible <BR> &nbsp;&nbsp; ❑ If HCT increases: continue colloid at 10–20 ml/kg for 1 h
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL><sup>†</sup> Hospital Acquired Meningitis; Posttraumatic Meningitis; Postneurosurgery &nbsp; Meningitis; Neutropenia; Impaired Cell-mediated Immunity</SMALL>
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5; font-weight: bold; font-style: italic;" align=center | Management of hemorrhagic complications
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ❑ Give 5–10 ml/kg of packed red cells or 10–20 ml/kg of whole blood
|}
|}
|}
|}
|}
|}

Latest revision as of 17:44, 14 July 2014

Testing area

Multiple Tables

  • 0.
Disease Findings
DISEASE NAME PRESENTS WITH_____
DISEASE NAME PRESENTS WITH____


  • 1.
Unfavorable Prognostic Factors
  ▸  Presenting with encephalopathy or coma
  ▸  Younger than 10 years or elderly
  ▸  Late start of antibiotics
  ▸  Sterile cultures
Favorable prognostic factors
  ▸  Craniotomy instead of burr holes as surgical procedure
  ▸  Early treatment
  ▸  Young age (optimal between 10-20 years)
  ▸  Patient presents awake, alert and oriented
  ▸  Source of infection: paranasal sinuses
  ▸  Aerobic streptococci isolated in culture
  ▸  Aerobic streptococci as single pathogen
  • 2.

Unfavorable Prognostic Factors
  ▸  Presenting with encephalopathy or coma
  ▸  Younger than 10 years or elderly
  ▸  Late start of antibiotics
  ▸  Sterile cultures
Favorable Prognostic Factors
  ▸  Craniotomy instead of burr holes as surgical procedure
  ▸  Early treatment
  ▸  Young age (optimal between 10-20 years)
  ▸  Patient presents awake, alert and oriented
  ▸  Source of infection: paranasal sinuses
  ▸  Aerobic streptococci isolated in culture
  ▸  Aerobic streptococci as single pathogen

  • 3.
Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect No underlying causes
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease No underlying causes
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes
  • 4.
Group A (May be sent home)
  ▸  Group criteria
❑ Patients who do not have warning signs
PLUS
❑ Able to tolerate adequate volumes of oral fluids
OR
❑ Able to pass urine at least once every 6 hours
  ▸  Laboratory tests
❑ Complete blood count
❑ Hematocrit (Hct)
  ▸  Management
❑ Adequate bed rest
❑ Adequate fluid intake
❑ Acetaminophen (Paracetamol)
  ▸  Monitoring
❑ Patients with stable Hct may be sent home.
❑ Daily review for disease progression:
   ❑ Decreasing white blood cell count
   ❑ Defervescence
   ❑ Warning signs (until out of critical period)
❑ Immediate return to hospital if development of any warning signs
❑ Written advice for management
Group B (Referred for in-hospital care)
  ▸  Group criteria
❑ Patients with any of the warning signs:
   ❑ Abdominal pain or tenderness
   ❑ Persistent vomiting
   ❑ Clinical fluid accumulation
   ❑ Mucosal bleed
   ❑ Lethargy, restlessness
   ❑ Liver enlargment >2 cm
   ❑ Increase in hematocrit with rapid decrease in platelet count
  ▸  Laboratory tests
❑ Complete blood count
❑ Hematocrit (Hct)
  ▸  Management
❑ Obtain reference Hct before fluid therapy
❑ Give isotonic solutions such as 0.9 % saline or Ringer’s Lactate
   ❑ Start with 5–7 ml/kg/h for 1–2 h
   ❑ Then reduce to 3–5 ml/kg/h for 2–4 h
   ❑ Then reduce to 2–3 ml/kg/h or less according to clinical response
Reassess clinical status and repeat Hct
❑ If Hct remains the same or rises only minimally:
   ❑ Continue with 2–3 ml/kg/h for another 2–4 h
❑ If worsening of vital signs and rapidly rising Hct:
   ❑ Increase rate to 5–10 ml/kg/h for 1–2 h
Adjust fluid infusion rates
❑ Reduce intravenous fluids gradually when:
   ❑ Adequate urine output and/or fluid intake
   ❑ Hct deceases below the baseline value in a stable patient
  ▸  Monitoring
❑ Vital signs and peripheral perfusion (q1–4 until out of critical phase):
   ❑ Urine output (4–6 hourly)
   ❑ Hct (before and after fluid replacement, then 6–12 hourly)
   ❑ Blood glucose
   ❑ Renal function
   ❑ Liver function
   ❑ Coagulation profile
Group C (Require emergency treatment)
  ▸  Group criteria
❑ Patients with any of the warning signs:
   ❑ Abdominal pain or tenderness
   ❑ Persistent vomiting
   ❑ Clinical fluid accumulation
   ❑ Mucosal bleed
   ❑ Lethargy, restlessness
   ❑ Liver enlargment >2 cm
   ❑ Increase in hematocrit with rapid decrease in platelet count
  ▸  Laboratory tests
❑ Complete blood count
❑ Hematocrit (Hct)
❑ Other organ function tests as indicated
  ▸  Management
Management of compensated shock
❑ Resuscitation with isotonic crystalloid at 5–10 ml/kg/h over 1 hour
❑ If patient improves:
   ❑ Reduce IV fluids gradually to 5–7 ml/kg/h for 1–2 h
   ❑ Then to 3–5 ml/kg/h for 2–4 h
   ❑ Then to 2–3 ml/kg/h for 2–4 h
   ❑ Then reduced further depending on hemodynamic status
   ❑ IV fluids can be maintained for up to 24–48 h
❑ If patient is still unstable:
   ❑ Check Hct after first bolus
   ❑ If Hct increases: repeat a second bolus at 10–20 ml/kg/h for 1 h
   ❑ If Hct decreases: transfuse as soon as possible
Management of hypotensive shock
❑ Resuscitation with crystalloid/colloid at 20 ml/kg for 15 min
❑ If patient improves:
   ❑ Control rate at 10 ml/kg/h for 1 h, then reduce gradually
❑ If patient is still unstable:
   ❑ Review the HCT taken before the first bolus
   ❑ If HCT was low: transfuse as soon as possible
   ❑ If HCT was high: IV colloids at 10–20 ml/kg for 0.5–1 h
   ❑ If patient is improving: reduce the rate to 7–10 ml/kg/h for 1–2 h
❑ If patient is still unstable after second bolus:
   ❑ If HCT decreases: transfuse as soon as possible
   ❑ If HCT increases: continue colloid at 10–20 ml/kg for 1 h
Management of hemorrhagic complications
❑ Give 5–10 ml/kg of packed red cells or 10–20 ml/kg of whole blood